FOXA1 and breast carcinoma: Therefore, FOXA1, a biomarker with the potential to simultaneously screen for sensitivity to NAC and PARP inhibitors in breast cancer patients, holds significant clinical translational promise for future clinical application, facilitating the development of personalized treatment regimens.